MedTrace Logo

A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus

NCT05917288 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-11-14

Study results available
· View outcomes & findings →

Summary

This study will evaluate the pharmacokinetic characteristics and safety of belimumab subcutaneous (SC) in Chinese pediatric participants with SLE who have completed 48 weeks belimumab Intravenous (IV) treatment in 213560 study (NCT04908865)

Conditions

Interventions

BIOLOGICAL

Belimumab

Belimumab will be administered

DRUG

Standard of care

Standard of care will be administered

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GSK Clinical Trials

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-07
Primary Completion
2024-10-30
Completion
2024-10-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05917288 on ClinicalTrials.gov